Central Nervous SystemPsychiatryAddictionSleep TechnologyNeurologyBiotechnologyHealth CarePharmaceutical
Description
Alkermes plc (Alkermes), a global biopharmaceutical company, seeks to develop innovative medicines in the field of neuroscience.
The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependenc…
Analysis
Middle-of-the-road
Alkermes plc sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.
On valuation, the picture is expensive. The owner-earnings multiple stands at 47.4×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 18% a year, against analyst forecasts of -6%. The market is pricing in far more than analysts expect: heroic expectations.
Growth is tepid; the safety picture is stretched. The company scores 8/20 on our value-creation score: creating some value.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Mar 202694
84
2026
All-time high
94
Mar 2026
All-time low
84
Jun 2026
Average rank
89
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
55
—
—
—
Price/Earnings
7
—
—
—
Price/Book
28
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
9
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.